骨壊死治療の世界市場：2025年～2033年

世界の骨壊死治療の市場規模は、2024年に2億5,322万米ドルとなりました。同市場は、2033年には4億301万米ドルに達し、2025年～2033年の予測期間中のCAGRは5.9％と予測されています。

血管壊死、無菌性壊死、虚血性骨壊死とも呼ばれる骨壊死は、骨の軟骨下領域への血流の遮断によって引き起こされる骨の変性疾患で、骨細胞の死につながります。この病態は、体重を支える関節にある長骨の骨端に最もよく発症し、重症の場合は軟骨下骨を破壊したり、関節全体の崩壊を引き起こしたりします。

大腿骨頭、膝、距骨、上腕骨頭が骨壊死の最も頻度の高い部位であり、中でも股関節が最もよく侵される関節です。あまり一般的ではありませんが、手根骨や顎など他の骨に起こることもあります。骨壊死の効果的な管理には、早期発見と介入が重要です。当レポートでは、骨壊死の原因とそのメカニズム、そして最も一般的な罹患部位の病態と治療法を探ります。

骨壊死の発生率の上昇は、世界の骨壊死治療市場を拡大する重要な促進要因です。骨壊死と診断される患者が増えるにつれ、効果的な治療オプションに対する需要が高まり、市場成長に拍車をかけています。世界人口の高齢化は、骨壊死症例数の増加に寄与する主な要因です。高齢者は、特に股関節で骨壊死を発症するリスクが高いです。世界保健機関（WHO）によると、2030年までに6人に1人が60歳以上になり、2050年までに60歳以上の人口は21億人に達します。

骨壊死は60歳以上の高齢者に最も多く、股関節が最も頻繁に侵されます。特に交通事故による外傷が、特に若年層における骨壊死の増加に大きく寄与しています。2023年12月の世界保健機関（WHO）のデータによると、年間約119万人が交通事故が原因で死亡しています。交通事故による傷害は、5～29歳の小児および若年成人の死亡原因の第1位です。外傷の増加に伴い、骨壊死の症例数も増加します。そのため、関節温存手術、骨切り術、人工関節置換術といった治療法の需要が高まっています。

骨壊死は最も一般的には股関節に起こるが、上腕骨、膝、距骨にも起こりうる。月状骨のような手首の小さな骨ではあまり見られません。顎にも起こることがありますが、この総説では整形外科医がよく目にする形態に焦点を当てます。2023年8月の米国生物工学情報センター（NCBI）のデータによると、米国では、人工股関節全置換術の10％が血管壊死（AVN）によるものであり、一般的に30～65歳が罹患しています。

副腎皮質ステロイドの使用、生活習慣病、外傷、高齢化などが原因となる骨壊死の発生率の上昇は、世界の骨壊死治療市場に大きな影響を与えています。このような負担の増加は、薬理学的治療と外科的治療の両方における技術革新を推し進め、骨壊死管理を整形外科および再生医療業界における成長分野にしています。

ビスフォスフォネート関連顎骨壊死（BRONJ）の発症リスクを高める要因はいくつかあり、これが世界の骨壊死治療市場の抑制要因となっています。2023年7月の米国立生物工学情報センター（NCBI）のデータによると、抜歯、歯周病治療、口腔インプラント、入れ歯の使用などの歯科手術は、骨のターンオーバーを高め、骨壊死のリスクを高める可能性があります。がん、化学療法、低ヘモグロビン血症、糖尿病、腎透析、高血圧、高脂血症、高コレステロール血症などの開発は、BRONJの発症リスクをさらに高めます。

コルチコステロイド、H2ブロッカー、血管新生阻害剤（スニチニブ、ベバシズマブなど）、エリスロポエチン、シクロホスファミド療法などの薬剤は、骨代謝や免疫反応に影響を与えるため、BRONJのリスクを高める可能性があります。ファルネシルピロリン酸合成酵素またはCYP2C8の多型などの特定の遺伝因子は、特に多発性骨髄腫患者において、ビスフォスフォネート関連骨壊死の素因となる可能性があります。年齢、飲酒、およびタバコの使用は、骨壊死を発症する可能性をさらに高め、治療選択肢を複雑にします。

当レポートでは、世界の骨壊死治療市場について調査し、市場の概要とともに、タイプ別、治療別、投与経路別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 経営者の洞察と重要なポイント

第3章 市場力学

• 影響要因
  • 促進要因
  • 抑制要因
  • 機会
  • 影響分析

第4章 戦略的洞察と業界展望

• 市場のリーダーとパイオニア
• CXOの視点
• 最新の開発とブレークスルー
• 規制と償還の情勢
• ポーターのファイブフォース分析
• サプライチェーン分析
• 特許分析
• SWOT分析
• アンメットニーズとギャップ
• 市場参入と拡大のための推奨戦略
• シナリオ分析ベストケース、ベースケース、ワーストケースの予測
• 価格分析と価格動向
• キーオピニオンリーダー

第5章 骨壊死治療市場（タイプ別）

• 外傷性
• 非外傷性

第6章 骨壊死治療市場（治療別）

• 非ステロイド性抗炎症薬
• 血液凝固阻止剤
• コレステロール低下薬
• 骨粗鬆症治療薬
• ビスホスホネート
• その他

第7章 骨壊死治療市場（投与経路別）

• 経口
• 非経口

第8章 骨壊死治療市場、地域別市場分析と成長機会

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他
• 南米
  • ブラジル
  • アルゼンチン
  • その他
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他
• 中東・アフリカ

第9章 競合情勢と市場ポジショニング

• 競合状況の概要と主要市場参入企業
• 市場シェア分析とポジショニングマトリックス
• 戦略的パートナーシップ、合併・買収
• 製品ポートフォリオとイノベーションにおける主な発展
• 企業ベンチマーク

第10章 企業プロファイル

• Pfizer Inc.
• 会社概要
• 製品ポートフォリオ
• 財務概要
• 主な発展
• SWOT分析
• Haleon Group of Companies
• BASF Corporation
• Johnson &Johnson
• Bayer AG
• Sanofi
• Upsher-Smith Laboratories, LLC.
• Merck &Co., Inc
• Procter &Gamble Pharmaceuticals, Inc.
• Novartis AG
• Eugia US
• Dr. Reddy's Laboratories
• Amgen Inc.

第11章 仮定と調査手法

第12章 付録

The global osteonecrosis treatment market reached US$ 253.22 million in 2024 and is expected to reach US$ 403.01 million by 2033, growing at a CAGR of 5.9 % during the forecast period of 2025-2033.

Osteonecrosis, also referred to as avascular necrosis, aseptic necrosis, or ischemic bone necrosis, is a degenerative bone condition caused by the interruption of blood flow to the bone's subchondral area, leading to the death of bone cells. This condition most commonly affects the epiphysis of long bones at weight-bearing joints and, in severe cases, can destroy the subchondral bone or cause the collapse of an entire joint.

The femoral head, knee, talus, and humeral head are the most frequent sites for osteonecrosis, with the hip being the most commonly affected joint. Less commonly, it can occur in other bones such as the carpus or jaw. Early detection and intervention are crucial for the effective management of osteonecrosis. This activity explores the causes and mechanisms behind the disease and the presentation and treatment options for the most commonly affected areas.

Market Dynamics: Drivers & Restraints

Rising Incidence of Osteonecrosis

The growing incidence of osteonecrosis is a significant driver for expanding the global osteonecrosis treatment market. As more individuals are diagnosed with this condition, the demand for effective treatment options increases, fueling market growth. The aging global population is a major factor contributing to the rising number of osteonecrosis cases. Older individuals are at a higher risk of developing osteonecrosis, particularly in the hip joint. According to the World Health Organization (WHO), by 2030, 1 in 6 people will be aged 60 or older, and by 2050, the number of people aged 60 and above will reach 2.1 billion.

Osteonecrosis is most common in individuals aged 60 and above, with the hip joint being the most frequently affected. Traumatic injuries, particularly from road accidents, are key contributors to the rise in osteonecrosis, especially in younger individuals. As per World Health Organization (WHO) data in December 2023, around 1.19 million people die annually due to road traffic accidents. Road traffic injuries are the leading cause of death among children and young adults aged 5 to 29 years. As the number of traumatic injuries increases, so will the number of osteonecrosis cases. This increases the demand for treatment options like joint preservation surgery, osteotomy, and arthroplasty.

Osteonecrosis most commonly affects the hip but can also occur in the humerus, knee, and talus. It is less frequently seen in the smaller bones of the wrist, like the lunate. While it can also impact the jaw, this review focuses on the more common forms seen by orthopedic surgeons. According to the National Center for Biotechnology Information (NCBI) data in August 2023, in the United States, 10% of total hip arthroplasties are performed due to avascular necrosis (AVN), typically affecting individuals aged 30 to 65.

The increasing incidence of osteonecrosis, driven by corticosteroid use, lifestyle diseases, trauma, and an aging population, is significantly impacting the global osteonecrosis treatment market. This rising burden is pushing forward innovations in both pharmacological and surgical treatments, making osteonecrosis management a growing segment within the orthopedic and regenerative medicine industries.

Adverse Side Effects Associated with Treatment

Several factors increase the risk of developing bisphosphonate-related osteonecrosis of the jaw (BRONJ), which can act as a restraint in the global osteonecrosis treatment market. According to the National Center for Biotechnology Information (NCBI) data in July 2023, dental surgeries such as tooth extractions, periodontal treatments, oral implants, and the use of dentures can heighten bone turnover and increase the risk of osteonecrosis. Conditions like cancer, chemotherapy, low hemoglobin, diabetes, renal dialysis, hypertension, hyperlipidemia, and hypercholesterolemia further elevate the risk of developing BRONJ.

Drugs such as corticosteroids, H2 blockers, antiangiogenic agents (e.g., sunitinib, bevacizumab), erythropoietin, and cyclophosphamide therapy can increase the risk of BRONJ by affecting bone metabolism and immune response. Certain genetic factors, such as polymorphisms in farnesyl pyrophosphate synthase or CYP2C8, may predispose individuals to bisphosphonate-associated osteonecrosis, particularly in patients with multiple myeloma. Age, alcohol consumption, and tobacco use can further increase the likelihood of developing osteonecrosis, complicating treatment options.

Segment Analysis

The global osteonecrosis treatment market is segmented based on type, treatment, route of administration, and region.

Treatment:

The non-steroidal anti-inflammatory drugs segment in treatment is expected to dominate the global osteonecrosis treatment market with the highest market share

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used as a first-line treatment to manage pain and inflammation associated with osteonecrosis, a condition characterized by the death of bone tissue due to reduced blood supply. NSAIDs work by inhibiting cyclooxygenase (COX) enzymes, reducing the production of prostaglandins, which are responsible for inflammation and pain. In osteonecrosis, NSAIDs are primarily prescribed to provide symptomatic relief and to manage associated conditions such as arthritis.

The increasing prevalence of osteonecrosis due to factors such as prolonged corticosteroid use, alcohol consumption, trauma, and autoimmune diseases is driving demand for NSAIDs.Due to concerns over opioid addiction, many healthcare providers prefer NSAIDs as a safer alternative for pain management.NSAIDs are available in oral, topical, and injectable forms, offering flexibility in administration for different patient needs. With an aging population prone to bone-related conditions like osteoporosis and osteonecrosis, NSAID demand is expected to grow. These factors have solidified the segment's position in the global osteonecrosis treatment market.

Geographical Analysis

North America is expected to hold a significant position in the global osteonecrosis treatment market, with the highest market share

Osteonecrosis is a significant cause of hip arthroplasties in the U.S., affecting individuals primarily between the ages of 30 and 65. Around 10% of total hip replacements are due to avascular necrosis, indicating a strong demand for treatment solutions. The increasing number of elderly individuals in North America contributes to the demand for osteonecrosis treatments. In the U.S., 17% of the population was 65 or older in 2022, and this demographic is at a higher risk of developing osteonecrosis, further driving market growth.

The development of innovative treatment options, such as ozone injections for medication-related osteonecrosis of the jaw (MRONJ), is expected to boost the market. These treatments provide effective alternatives to surgical intervention for complex cases. The market has seen several approvals for osteonecrosis-related medications. For instance, in June 2022, Strides Pharma received FDA approval for its Ibuprofen suspension. The U.S. market for this product is estimated to be approximately $41 million, and it will be produced at the company's facility in Bengaluru. Thus, the above factors are consolidating the region's position as a dominant force in the global osteonecrosis treatment market.

Competitive Landscape

The major global players in the osteonecrosis treatment market include Pfizer Inc., Haleon Group of Companies, BASF Corporation, Johnson & Johnson, Bayer AG, Sanofi, Upsher-Smith Laboratories, LLC., Merck & Co., Inc., Procter & Gamble Pharmaceuticals, Inc., Novartis AG, Eugia US, Dr. Reddy's Laboratories, and Amgen Inc. among others.

Key Developments

• In March 2023, Perrigo Company plc, a leading provider of Consumer Self-Care Products, announced that it had received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global osteonecrosis treatment market report delivers a detailed analysis with 71 key tables, more than 56 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

• 1.1. Objectives of the Report
• 1.2. Report Coverage & Definitions
• 1.3. Report Scope

2. Executive Insights and Key Takeaways

• 2.1. Market Highlights and Strategic Takeaways
• 2.2. Key Trends and Future Projections
• 2.3. Snippet by Type
• 2.4. Snippet by Treatment
• 2.5. Snippet by Route of Administration
• 2.6. Snippet by Region

3. Dynamics

• 3.1. Impacting Factors
  • 3.1.1. Drivers
    • 3.1.1.1. Rising Incidence of Osteonecrosis
    • 3.1.1.2. Advancements in Medical Technology
  • 3.1.2. Restraints
    • 3.1.2.1. Adverse Side Effects Associated with Treatment
    • 3.1.2.2. High Costs Associated with Surgical Treatments
  • 3.1.3. Opportunity
    • 3.1.3.1. Demand for Non-Invasive Treatments
  • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

• 4.1. Market Leaders and Pioneers
  • 4.1.1. Emerging Pioneers and Prominent Players
  • 4.1.2. Established leaders with the largest-selling Brand
  • 4.1.3. Market leaders with established Product
• 4.2. CXO Perspectives
• 4.3. Latest Developments and Breakthroughs
• 4.4. Regulatory and Reimbursement Landscape
  • 4.4.1. North America
  • 4.4.2. Europe
  • 4.4.3. Asia Pacific
  • 4.4.4. South America
  • 4.4.5. Middle East & Africa
• 4.5. Porter's Five Forces Analysis
• 4.6. Supply Chain Analysis
• 4.7. Patent Analysis
• 4.8. SWOT Analysis
• 4.9. Unmet Needs and Gaps
• 4.10. Recommended Strategies for Market Entry and Expansion
• 4.11. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 4.12. Pricing Analysis and Price Dynamics
• 4.13. Key Opinion Leaders

5. Osteonecrosis Treatment Market, By Type

• 5.1. Introduction
  • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 5.1.2. Market Attractiveness Index, By Type
• 5.2. Traumatic*
  • 5.2.1. Introduction
  • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 5.3. Nontraumatic

6. Osteonecrosis Treatment Market, By Treatment

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 6.1.2. Market Attractiveness Index, By Treatment
• 6.2. Non-Steroidal Anti-Inflammatory Drugs*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.2.3. Ibuprofen
  • 6.2.4. Naproxen Sodium
• 6.3. Blood Thinners
  • 6.3.1. Warfarin
  • 6.3.2. Enoxaparin
• 6.4. Cholesterol-Lowering Drugs
• 6.5. Osteoporosis Drugs
• 6.6. Bisphosphonates
  • 6.6.1. Alendronate
  • 6.6.2. Risedronate
  • 6.6.3. Zoledronic Acid
  • 6.6.4. Ibandronate
• 6.7. Others

7. Osteonecrosis Treatment Market, By Route of Administration

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 7.1.2. Market Attractiveness Index, By Route of Administration
• 7.2. Oral*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Parenteral

8. Osteonecrosis Treatment Market, By Regional Market Analysis and Growth Opportunities

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.2.6.1. U.S.
    • 8.2.6.2. Canada
    • 8.2.6.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.3.6.1. Germany
    • 8.3.6.2. U.K.
    • 8.3.6.3. France
    • 8.3.6.4. Spain
    • 8.3.6.5. Italy
    • 8.3.6.6. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.4.6.1. Brazil
    • 8.4.6.2. Argentina
    • 8.4.6.3. Rest of South America
• 8.5. Asia-Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.5.6.1. China
    • 8.5.6.2. India
    • 8.5.6.3. Japan
    • 8.5.6.4. South Korea
    • 8.5.6.5. Rest of Asia-Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

9. Competitive Landscape and Market Positioning

• 9.1. Competitive Overview and Key Market Players
• 9.2. Market Share Analysis and Positioning Matrix
• 9.3. Strategic Partnerships, Mergers & Acquisitions
• 9.4. Key Developments in Product Portfolios and Innovations
• 9.5. Company Benchmarking

10. Company Profiles

• 10.1. Pfizer Inc.*
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio
    • 10.1.2.1. Product Description
    • 10.1.2.2. Product Key Performance Indicators (KPIs)
    • 10.1.2.3. Historic and Forecasted Product Sales
    • 10.1.2.4. Product Sales Volume
  • 10.1.3. Financial Overview
    • 10.1.3.1. Company Revenue
    • 10.1.3.2. Geographical Revenue Shares
    • 10.1.3.3. Revenue Forecasts
  • 10.1.4. Key Developments
    • 10.1.4.1. Mergers & Acquisitions
    • 10.1.4.2. Key Product Development Activities
    • 10.1.4.3. Regulatory Approvals, etc.
  • 10.1.5. SWOT Analysis
• 10.2. Haleon Group of Companies
• 10.3. BASF Corporation
• 10.4. Johnson & Johnson
• 10.5. Bayer AG
• 10.6. Sanofi
• 10.7. Upsher-Smith Laboratories, LLC.
• 10.8. Merck & Co., Inc
• 10.9. Procter & Gamble Pharmaceuticals, Inc.
• 10.10. Novartis AG
• 10.11. Eugia US
• 10.12. Dr. Reddy's Laboratories
• 10.13. Amgen Inc.

LIST NOT EXHAUSTIVE

11. Assumptions and Research Methodology

• 11.1. Data Collection Methods
• 11.2. Data Triangulation
• 11.3. Forecasting Techniques
• 11.4. Data Verification and Validation

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us